Catalym Gmbh

This study tests whether adding the experimental drug visugromab to standard chemotherapy and immunotherapy can shrink tumors better than placebo in people with newly diagnosed metastatic non-squamous non-small cell lung cancer. About 107 adults who have not had prior treatment f…

This study tests whether adding visugromab to standard treatments (nivolumab and lenvatinib) can help people with advanced liver cancer that has stopped responding to initial therapy. About 104 adults with unresectable or metastatic hepatocellular carcinoma and good liver functio…

This study tests whether adding the experimental drug visugromab to standard immunotherapy and chemotherapy can shrink tumors better than chemotherapy alone in people with advanced non-squamous lung cancer. About 131 participants who have already tried one prior treatment will re…

This study tests a new drug called visugromab in about 518 people with advanced lung or bowel cancer who are losing weight unintentionally (cachexia). The goal is to see if the drug helps patients gain weight, improve appetite, and move better compared to a placebo. Participants …